Dr. Saurabh Lall joins KIMS Hospitals as Chief Operating Officer

Dr. Lall brings extensive experience in healthcare operations, business strategy, and hospital management

Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6

First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

The safety profile was described as manageable, though not without notable toxicities

M|O|C Cancer Care’s research gains global recognition at ASCO 2026

The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care

STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial

While overall survival data remain immature, the results pointed to a favourable trend.

Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance

Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting

The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial

Fermenta Biotech reports 26% revenue growth in FY26

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors